Rui Li

Dr. Rui Li

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2004 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
RLRui Li
Rui Li
YHYuan‐Gui Huang
Yuan‐Gui Huang
DFDu Fang
Du Fang
WLWeidong Le
Weidong Le

23 November 2005 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
FDFang Du
Fang Du
RLRui Li
Rui Li
YHYuangui Huang
Yuangui Huang
XLXuping Li
Xuping Li
WLWeidong Le
Weidong Le

12 July 2005 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
XLXuan Liu
Xuan Liu
XFXiao‐Lan Fan
Xiao‐Lan Fan
YZYan Zhao
Yan Zhao
GLGuang‐Rui Luo
Guang‐Rui Luo
XLXu‐Ping Li
Xu‐Ping Li
WLWeidong Le
Weidong Le

22 December 2014 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
PTPeng Tang
Peng Tang
LCLi Chong
Li Chong
XLXiaoqing Li
Xiaoqing Li
YLYue Liu
Yue Liu
PLPeng Liu
Peng Liu
RLRui Li
Rui Li
Inflammatory mediators may reflect a role of systemic inflammation in the neurodegenerative process of Parkinson’s disease (PD). Interleukin-6 (IL-6) and chemokine ligand 5 (CCL5), also known as RANTES (regulated on activation, normal T cell expressed and secreted), have been implicated in neurodegenerative diseases including PD. Serum levels of RANTES and IL-6 of 78 consecutive PD patients and age-matched 80 controls were measured. Patients with PD had higher RANTES and IL-6 levels compared with the controls. We found that serum RANTES levels strongly correlated with Hoehn-Yahr score and disease duration in PD patients. This study indicated that patients with PD have an on-going systemic inflammatory profile where the elevated peripheral production of RANTES may play a role in the neurodegenerative process.

29 March 2008 in International Journal of Developmental Neuroscience
Verified
Journal Article
Closed access
HSHong Sun
Hong Sun
YHYuangui Huang
Yuangui Huang
XYXin Yu
Xin Yu
YLYongnan Li
Yongnan Li
JYJun Yang
Jun Yang
GZGang Zhao
Gang Zhao

31 March 2023 in Journal of Epidemiology and Community Health
Verified
Journal Article
Closed access
PDF file
XGXingzhi Guo
Xingzhi Guo
PTPeng Tang
Peng Tang
LZLina Zhang
Lina Zhang
RLRui Li
Rui Li
Background Epidemiological data have suggested that tobacco and alcohol consumption were associated with the risk of frailty and falling, but it is yet unclear whether these associations are of a causal nature. Thus, we conducted two-sample Mendelian randomisation analysis using genetic instruments to determine the causal associations of tobacco and alcohol consumption on frailty and falls. Methods Independent instrumental variables strongly (p<5E–09) associated with tobacco and alcohol consumption were obtained from the genome-wide association study (GWAS) and Sequencing Consortium of Alcohol and Nicotine use (up to 2 669 029 participants). Summary statistics of the frailty index (FI, N=175 226) and falling risk (N=451 179) were from the two latest published GWAS datasets on FI and falling risk. Results Using the inverse-variance weighted method, our results showed that genetically determined initiation of smoking was significantly associated with an increased FI (β=0.34, 95% CI=0.29 to 0.40, p=5.48E–33) and risk of falling (OR=1.39, 95% CI=1.30 to 1.50, p=1.01E–20). In addition, the age of initiation of smoking and cigarettes consumption per day was negatively and positively associated with both FI and falls, respectively. Current smokers were prone to having a higher FI and falling risk than individuals who quit smoking. There was no significant causal association between alcohol use and the risk of frailty and falling. Similar results were obtained using other statistical approaches with good stability. Conclusions Our findings demonstrate that tobacco use, but not alcohol drinking, significantly increases the risk of frailty and falling. Future studies are warranted to clarify the underlying physiopathological mechanisms.